2022 noqon kara: FDA waxay ogolaatay codsiga tijaabada kiliinikada ee daaweynta gaarka ah ee CAR-NK FT536 ee daawaynta burooyinka adag ee tijaabada caafimaad ee CAR-NK. FDA waxay ansixisay Codsiga Dawo Cusub ee Baadhitaanka Janaayo 2022 ee daawaynta CAR-NK FT536 si loogu daweeyo shakhsiyaadka soo noqnoqday ama u adkaysta xumaanta adag. Tijaabadaan, bukaanada qaba kansarka sanbabada unug yar oo horumarsan, kansarka mindhicirka, kansarka madaxa iyo qoorta, kansarka caloosha, kansarka naasaha, kansarka ugxansidaha, iyo kansarka ganaca waxay heli doonaan FT536 sida monotherapy ama marka lagu daro monoclonal antibody. FT536 (Daawaynta qaddarka) waa allogeneic, daawaynta unugyada dabiiciga ah ee badan-engineered (NK) oo laga soo saaray unugyo tamar badan leh.
Kani waa daawaynta unugyada NK ee hidde ahaan loo farsameeyay oo muujisa CAR kaas oo bartilmaameedsada qaybaha alfa-3 ee MICA iyo MICB, laba borotiino oo ku lug leh fasalka adag ee histocompatibility ee ugu weyn daadinta si loo soo celiyo difaaca burada oo ay dhexdhexaadiyaan unugyada NK iyo T. Guud ahaan, FT536 waxa ay ka kooban tahay afar isbeddel oo shaqayneed: CAR iska leh oo beegsanaya MICA iyo MICB's 3; 158V cusub oo cusub, CD16 (hnCD16) Fc reseptor oo kor u qaadaya ADCC; waxay kor u qaadaysaa unugyada NK ee firfircoon ee IL-15 fusion receptor (IL-15RF); iyo baabi'inta muujinta CD38, taas oo kor u qaadaysa fayaqabka dheef-shiid kiimikaadka unugyada NK, adkaysiga, iyo shaqada antitumor.
We expect that FT536 therapy can obtain positive data as soon as possible in clinical trials of solid burooyinka, and it will be launched as soon as possible to benefit patients.
